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1. INTRODUCTION {#clc23223-sec-0005}
===============

Aortic dissection (AD) is a life threating disease once left undiagnosed or untreated.[1](#clc23223-bib-0001){ref-type="ref"}, [2](#clc23223-bib-0002){ref-type="ref"} The phenomenon of AD presenting with atrial fibrillation (AF) has indeed been discussed previously[3](#clc23223-bib-0003){ref-type="ref"}, [4](#clc23223-bib-0004){ref-type="ref"}, [5](#clc23223-bib-0005){ref-type="ref"}, [6](#clc23223-bib-0006){ref-type="ref"}, [7](#clc23223-bib-0007){ref-type="ref"}, [8](#clc23223-bib-0008){ref-type="ref"}, [9](#clc23223-bib-0009){ref-type="ref"}; in case of subclinical AD, AF may occur and be a sign of alert. For clinicians who care for patients with AF, it is well known that stroke, heart failure, and death are common AF complications.[10](#clc23223-bib-0010){ref-type="ref"}, [11](#clc23223-bib-0011){ref-type="ref"}, [12](#clc23223-bib-0012){ref-type="ref"} To date, whether there is an increased risk of AD in patients with AF remained unknown.

To provide additional evidence linking AD and AF from the view point of clinical aspect, investigation on the relationship between AF and AD might be thoughtful. Hence, we sought to utilize the Taiwanese national dataset to describe the incidence of AF in patients with AD and the incidence of AD in patients with AF, using propensity score methods, multivariate controlling and combining a large number of comorbidities in our analysis to explore the link between AD and AF.

2. METHODS {#clc23223-sec-0006}
==========

2.1. Data source {#clc23223-sec-0007}
----------------

We used the National Health Insurance Research Database (NHIRD) of the National Health Insurance (NHI) program in Taiwan to conduct this retrospective nationwide cohort study. The NHI program was established by the Taiwanese government on March 1, 1995, and it covered more than 99% of the 23.74 million residents in Taiwan. In this retrospective cohort study, the history of disease diagnosis was obtained from inpatient files, with data available from 1996 to 2011. The diagnoses in Taiwan NHI were coded according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD‐9‐CM). The Research Ethics Committee of China Medical University and Hospital in Taiwan approved the study (CMUH‐104‐REC2‐115‐R3).

2.2. Sampled participants {#clc23223-sec-0008}
-------------------------

For study 1, we identified patients aged 18 or older years with AD diagnosed between 2000 and 2010 (ICD‐9‐CM codes 441.0) and control individuals without AD. The index date for control patients was randomly appointed a month and day with the same index year of the matched AD cases. We defined the diagnosed date of AD as the index date for each patient. We excluded patients with a diagnosis of AF (ICD‐9‐CM codes 427.31) at baseline and those with incomplete medical records information. Patients in the AD and non‐AD cohorts were selected by 1:1 matching based on a propensity score.[13](#clc23223-bib-0013){ref-type="ref"} The propensity score was calculated using a logistic regression model to estimate the probability of the AD status assignment, based on the baseline variables including year of AD diagnosis, sex, age, and comorbidities of hypertension, diabetes mellitus (DM), hyperlipidemia, coronary heart disease (CHD), heart failure (HF), chronic obstructive pulmonary disease (COPD), peripheral artery disease (PAD), chronic kidney disease (CKD), hyperthyroidism, sleep disorders, gout, cerebrovascular disease, chronic liver disease, cancer, asthma, peptic ulcer disease, and vavular heart disease (VHD). For study 2, patients aged 18 or older years with AF diagnosed between 2000 and 2010 and control individuals without AF were identified. Patients suffering from AD at the baseline and those with missing medical records information were excluded. For each AF identified, controls were selected and matched by propensity score under the same exclusion criteria. The propensity score was calculated using a logistic regression model to estimate the probability of the AF status assignment, based on the baseline variables including year of AF diagnosis, sex, age, and comorbidities of hypertension, DM, hyperlipidemia, CHD, HF, COPD, PAD, CKD, hyperthyroidism, sleep disorders, gout, cerebrovascular disease, chronic liver disease, cancer, asthma, peptic ulcer disease, and VHD.

2.3. Outcome {#clc23223-sec-0009}
------------

Subjects in the study 1 were followed until the diagnosis of AF or until withdrawal from the NHI program or death, or December 31, 2011. Subjects in the study 2 were followed until the diagnosis of AD or until withdrawal from the NHI program or death, or December 31, 2011.

2.4. Statistical analysis {#clc23223-sec-0010}
-------------------------

For study 1, the distributions of the sex, age, and comorbidities were compared between the AD cohort and the non‐AD cohort, and the differences were examined using the standardized mean difference (SMD). A SMD of ≤0.10 indicates a negligible difference between the two cohorts. The overall, sex‐, age‐, comorbidity‐specific, and follow‐up period incidence densities rate of AF (per 1000 person‐years, PY) were measured for each cohort. Univariable and multivariable Cox proportion hazard regression models were used to examine the effect of AD on the risk of AF, shown as hazard ratios (HRs) with 95% confidence intervals (CIs). The multivariable‐adjusted models included covariates that were not adequately balanced in Tables [1](#clc23223-tbl-0001){ref-type="table"} and 3 (standardized difference \> 0.1). The cumulative incidence curve of AF was computed using the Kaplan‐Meier method and the differences between both cohorts were examined using the log‐rank test. Similar data analysis procedures were performed to calculate the incidence density rates of AD (per 1000 person‐years, PY) and HRs (95% CIs) for the AF and non‐AF cohorts in the study 2. Data analyses were conducted using statistical package SAS (Version 9.4, SAS Institute Inc., Carey, North Carolina). A two‐tailed *P* value \< .05 was considered statistically significant.

###### 

Demographic characteristics and comorbidities in patients with and without aortic dissection

                            Aortic dissection                        
  ------------------------- ------------------- ------ ------ ------ ------
  Sex                                                                
  Female                    3797                32.1   3375   28.6   0.08
  Male                      8016                67.9   8438   71.4   0.08
  Age, years                                                         
  20--49                    1488                12.6   2201   18.6   0.17
  50--64                    3015                25.5   3683   31.2   0.13
  ≥ 65                      7310                61.9   5929   50.2   0.24
  Mean (SD) ^†^             67.5                14.5   63.9   14.6   0.25
  Comorbidity                                                        
  Hypertension              8598                72.8   8357   70.7   0.05
  Diabetes mellitus         1964                16.6   1505   12.7   0.05
  Hyperlipidemia            1330                11.3   1149   9.73   0.05
  CHD                       2994                25.3   3078   26.1   0.02
  Heart failure             1048                8.87   1141   9.66   0.03
  COPD                      1205                10.2   1138   9.63   0.02
  PAD                       332                 2.81   426    3.61   0.05
  CKD                       457                 3.87   416    3.52   0.02
  Hyperthyroidism           90                  0.76   50     0.42   0.04
  Sleep disorders           337                 2.85   279    2.36   0.03
  Gout                      1013                8.58   979    8.29   0.01
  Cerebrovascular disease   2328                19.7   2290   19.4   0.01
  Chronic liver disease     987                 8.36   716    6.06   0.09
  Cancer                    764                 6.47   509    4.31   0.10
  Asthma                    735                 6.22   607    5.14   0.05
  Peptic ulcer disease      2345                19.9   1907   16.1   0.10
  VHD                       1207                10.2   1581   13.4   0.10

A standardized mean difference of ≤0.10 indicates a negligible difference between the two cohorts.

CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; PAD, peripheral artery disease; VHD, valvular heart disease.

3. RESULTS {#clc23223-sec-0011}
==========

3.1. Study 1 {#clc23223-sec-0012}
------------

The study 1 consisted of 11 813 patients in the AD cohort and 11 813 controls in the non‐AD cohort (Table [1](#clc23223-tbl-0001){ref-type="table"}). Men represented the majority of the study cohorts (71.4% vs 67.9%) and over a half of study population were more than 65 years old. The AD cohort were slightly younger than the non‐AD cohort. The average follow‐up duration was 3.71 ± 3.19 years for the AD cohort and 4.85 ± 2.99 years for the non‐AD cohort. Figure [1](#clc23223-fig-0001){ref-type="fig"}A shows that the cumulative incidence of AF was higher in the AD cohort than in the non‐AD cohort (the log‐rank test *P* \< .001) after 12 years of follow‐up.

![A, Cumulative incidence of atrial fibrillation (AF) for patients with (solid line) and without (dashed line) aortic dissection. B, Cumulative incidence of aortic dissection for patients with (solid line) and without (dashed line) AF](CLC-42-812-g001){#clc23223-fig-0001}

The overall incidence density of AF was 1.32‐fold higher in the AD cohort than in the non‐AD cohort (11.1 and 8.3 per 1000 person‐years), with an adjusted HR (aHR) of 1.74 (95% CI = 1.53‐1.98) after controlling for age (Table [2](#clc23223-tbl-0002){ref-type="table"}).

###### 

Incidence and hazard ratios of atrial fibrillation for aortic dissection cohort compared to non‐aortic dissection cohort by demographic characteristics, comorbidity and follow‐up year

                                                       Aortic dissection                                                                                                         
  ---------------------------------------------------- ------------------- -------- ------ ----- -------- ------ --------------------------------------------------------------- ---------------------------------------------------------------
  Total                                                475                 57 237   8.3    485   43 870   11.1   1.32 (1.17, 1.50)[\*\*\*](#clc23223-note-0008){ref-type="fn"}   1.74 (1.53, 1.98)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  Sex                                                                                                                                                                            
  Female                                               165                 18 081   9.13   161   12 147   13.3   1.44 (1.16, 1.79)[\*\*](#clc23223-note-0007){ref-type="fn"}     1.76 (1.42, 2.20)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  Male                                                 310                 39 157   7.92   324   31 723   10.2   1.29 (1.10, 1.50)[\*\*](#clc23223-note-0007){ref-type="fn"}     1.73 (1.48, 2.03)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  Age, years                                                                                                                                                                     
  20‐49                                                9                   8347     1.08   34    10 282   3.31   3.06 (1.47, 6.39)[\*\*](#clc23223-note-0007){ref-type="fn"}     
  50‐64                                                55                  16 269   3.38   90    15 555   5.79   1.71 (1.22, 2.39)[\*\*](#clc23223-note-0007){ref-type="fn"}     
  ≥65                                                  411                 32 620   12.6   361   18 033   20.0   1.59 (1.38, 1.83)[\*\*\*](#clc23223-note-0008){ref-type="fn"}   
  Comorbidity[a](#clc23223-note-0005){ref-type="fn"}                                                                                                                             
  No                                                   34                  6528     5.21   40    4820     8.30   1.59 (1.01, 2.52)[\*](#clc23223-note-0006){ref-type="fn"}       3.44 (2.11, 5.59)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  Yes                                                  441                 50 709   8.70   445   39 050   11.4   1.30 (1.14, 1.49)[\*\*\*](#clc23223-note-0008){ref-type="fn"}   1.64 (1.43, 1.87)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  Hypertension                                         383                 39 955   9.59   349   31 726   11.0   1.14 (0.99, 1.32)                                               1.51 (1.30, 1.74)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  DM                                                   96                  8260     11.6   75    4733     15.9   1.35 (1.00, 1.83)                                               1.51 (1.11, 2.04)[\*\*](#clc23223-note-0007){ref-type="fn"}
  Hyperlipidemia                                       56                  6134     9.13   54    4182     12.9   1.39 (0.96, 2.02)                                               1.51 (1.04, 2.20)[\*](#clc23223-note-0006){ref-type="fn"}
  CHD                                                  180                 13 295   13.5   184   10 628   17.3   1.27 (1.03, 1.56)[\*](#clc23223-note-0006){ref-type="fn"}       1.51 (1.23, 1.85)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  Heart failure                                        86                  3622     23.7   96    2861     33.6   1.41 (1.05, 1.88)[\*](#clc23223-note-0006){ref-type="fn"}       1.74 (1.29, 2.33)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  COPD                                                 95                  4700     20.2   80    3056     26.2   1.28 (0.95, 1.73)                                               1.32 (0.98, 1.78)
  PAD                                                  19                  1257     15.1   23    1203     19.1   1.23 (0.67, 2.26)                                               1.49 (0.80, 2.76)
  CKD                                                  22                  1632     13.5   23    1171     19.7   1.45(0.81, 2.61)                                                1.61(0.90, 2.90)
  Hyperthyroidism                                      5                   480      10.4   4     181      22.1   1.96 (0.52, 7.36)                                               1.58 (0.40, 6.22)
  Sleep disorders                                      11                  1345     8.18   14    994      14.1   1.73 (0.78, 3.81)                                               1.99 (0.90, 4.40)
  Gout                                                 53                  4344     12.2   52    3369     15.4   1.23 (0.84, 1.81)                                               1.45 (0.98, 2.13)
  Cerebrovascular disease                              101                 9646     10.5   116   6449     18.0   1.70 (1.30, 2.22)[\*\*\*](#clc23223-note-0008){ref-type="fn"}   2.00 (1.53, 2.61)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  Chronic liver disease                                38                  4336     8.76   32    2236     14.3   1.64 (1.02, 2.63)[\*](#clc23223-note-0006){ref-type="fn"}       1.63 (1.02, 2.61)[\*](#clc23223-note-0006){ref-type="fn"}
  Cancer                                               26                  2771     9.38   23    1315     17.5   1.87 (1.07, 3.28)[\*](#clc23223-note-0006){ref-type="fn"}       1.80 (1.02, 3.16)[\*](#clc23223-note-0006){ref-type="fn"}
  Asthma                                               54                  3129     17.3   49    1870     26.2   1.48 (1.00, 2.18)[\*](#clc23223-note-0006){ref-type="fn"}       1.41 (0.95, 2.07)
  Peptic ulcer disease                                 99                  10 366   9.55   98    6068     16.2   1.67 (1.26, 2.21)[\*\*\*](#clc23223-note-0008){ref-type="fn"}   1.78 (1.34, 2.35)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  VHD                                                  85                  5139     16.5   96    5856     16.4   1.00 (0.75, 1.34)                                               1.52 (1.13, 2.06)[\*\*](#clc23223-note-0007){ref-type="fn"}
  Follow‐up year                                                                                                                                                                 
  ≦1                                                   86                  11 454   7.51   144   9468     15.2   1.98 (1.52, 2.59)[\*\*\*](#clc23223-note-0008){ref-type="fn"}   2.44 (1.86, 3.20)[\*\*\*](#clc23223-note-0008){ref-type="fn"}
  2‐3                                                  168                 19 105   8.79   134   14 666   9.14   1.04 (0.83, 1.31)                                               1.41 (1.12, 1.78)[\*\*](#clc23223-note-0007){ref-type="fn"}
  4‐5                                                  106                 12 684   8.36   94    9584     9.81   1.17 (0.89, 1.55)                                               1.58 (1.19, 2.09)[\*\*](#clc23223-note-0007){ref-type="fn"}
  \>5                                                  115                 13 994   8.22   113   10 152   11.1   1.36 (1.05, 1.76)[\*](#clc23223-note-0006){ref-type="fn"}       1.82 (1.40, 2.37)[\*\*\*](#clc23223-note-0008){ref-type="fn"}

Rate^\#^, incidence rate per 1000 person‐years;

Abbreviations: CHD, coronary heart disease; CI; confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HR, hazard ratio; PAD, peripheral artery disease; VHD, valvular heart disease.

Patients with any comorbidity of hypertension, diabetes mellitus, hyperlipidemia, CHD, heart failure, COPD, PAD, CKD, hyperthyroidism, sleep disorders, gout, cerebrovascular disease, chronic liver disease, cancer, asthma, peptic ulcer disease, and VHD were defined as the comorbidity group.

*P* \< .05

*P* \< .01

*P* \< .001.

The incidence density and risk of AF were compared in the AD cohort and the non‐AD cohort regarding several variables including sex, age, with or without comorbidity, individual comorbidity and follow‐up period. The risk of AF in AD patients was also significantly higher than that of the non‐AD cohort in most stratified analysis (except for with comorbidity of COPD, PAD, CKD, hyperthyroidism, sleep disorders, gout, and asthma).

3.2. Study 2 {#clc23223-sec-0013}
------------

The study 2 consisted of 190 494 patients in the AF cohort and 190 494 controls in the non‐AF cohort (Table [3](#clc23223-tbl-0003){ref-type="table"}). Both cohorts had more men (54.9% vs 55.3%) and more than 75% of the study population were aged ≥ 65 years. The average follow‐up duration was 3.47 years for the AF cohort and 4.19 years for the non‐AF cohort.

###### 

Demographic characteristics and comorbidities in patients with and without atrial fibrillation

                                                     Atrial fibrillation                           
  -------------------------------------------------- --------------------- ------ --------- ------ -------
  Sex                                                                                              
  Female                                             85 117                44.7   85 883    45.1   0.01
  Male                                               105 377               55.3   104 611   54.9   0.01
  Age, years                                                                                       
  20‐49                                              6981                  3.66   10 398    5.46   0.09
  50‐64                                              25 770                13.5   29 875    15.7   0.06
  ≥65                                                157 743               82.8   150 221   78.9   0.10
  Mean (SD)[a](#clc23223-note-0010){ref-type="fn"}   74.7                  11.6   73.5      12.6   0.001
  Comorbidity                                                                                      
  Hypertension                                       126 175               66.2   109 709   57.6   0.18
  DM                                                 59 551                31.3   50 827    26.7   0.18
  Hyperlipidemia                                     27 603                14.5   22 241    11.7   0.08
  CHD                                                77 171                40.5   74 482    39.1   0.03
  Heart failure                                      47 807                25.1   63 957    33.6   0.19
  COPD                                               38 867                20.4   39 788    20.9   0.01
  PAD                                                5222                  2.74   5536      2.91   0.01
  CKD                                                10 819                5.68   10 466    5.49   0.01
  Hyperthyroidism                                    4267                  2.24   4222      2.22   0.002
  Sleep disorders                                    6835                  3.59   5904      3.10   0.03
  Gout                                               16 735                8.79   15 320    8.04   0.03
  Cerebrovascular disease                            69 200                36.3   62 115    32.6   0.08
  Chronic liver disease                              19 120                10.0   15 346    8.06   0.07
  Cancer                                             16 485                8.65   12 524    6.57   0.08
  Asthma                                             21 261                11.2   20 910    11.0   0.01
  Peptic ulcer disease                               44 930                23.6   38 175    20.0   0.09
  VHD                                                24 981                13.1   30 395    16.0   0.08

Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; PAD, peripheral artery disease; VHD, valvular heart disease.

A standardized mean difference of ≤0.10 indicates a negligible difference between the two cohorts.

Figure [1](#clc23223-fig-0001){ref-type="fig"}B shows that the cumulative incidence of AD was higher in the AF cohort than in the non‐AF cohort (the log‐rank test *P* = .01) after 12 years of follow‐up. The AF cohort had 1.18‐fold higher incidence of AD than the non‐AF cohort (0.55 vs 0.47 per 1000 person‐years), with an aHR of 1.24 (95% CI = 1.07‐1.44) (Table [4](#clc23223-tbl-0004){ref-type="table"}). The sex‐specific AD risk for the AF cohort relative to the non‐AF cohort was significantly higher for women (aHR = 1.37; 95% CI = 1.08‐1.75). The age‐specific AD risk for the AF cohort relative to the non‐AF cohort was higher for the aged 50 to 64 group (aHR = 1.56; 95% CI = 1.06‐2.28) and for the aged ≥65 group (aHR = 1.19; 95% CI = 1.01‐1.40). Among the comorbid subjects, patients with AF had a higher risk of AD compared to the non‐AF cohort (aHR = 1.20 for hypertension; aHR = 1.47 for diabetes mellitus; aHR = 1.67 for chronic liver disease; aHR = 1.37 for peptic ulcer disease). In the first year of follow‐up, the AF cohort had a higher risk of AD compared with the non‐AF cohort (aHR = 1.78, 95% CI = 1.34‐2.36).

###### 

Incidence and hazard ratios of aortic dissection for atrial fibrillation (AF) cohort compared to non‐AF cohort by demographic characteristics, comorbidity and follow‐up year

                                                       Atrial fibrillation                                                                                                           
  ---------------------------------------------------- --------------------- --------- ------ ----- --------- ------ --------------------------------------------------------------- ---------------------------------------------------------------
  Total                                                373                   799 500   0.47   365   662 905   0.55   1.18 (1.02, 1.36)[\*\*](#clc23223-note-0016){ref-type="fn"}     1.24 (1.07, 1.44)[\*\*](#clc23223-note-0016){ref-type="fn"}
  Sex                                                                                                                                                                                
  Female                                               130                   363 359   0.36   140   296 615   0.47   1.30 (1.03, 1.66)[\*](#clc23223-note-0015){ref-type="fn"}       1.37 (1.08, 1.75)[\*](#clc23223-note-0015){ref-type="fn"}
  Male                                                 243                   436 141   0.56   225   366 290   0.61   1.11 (0.92, 1.33)                                               1.19 (0.99, 1.44)
  Age, years                                                                                                                                                                         
  20‐49                                                8                     36 393    0.22   11    56 431    0.19   0.91 (0.37, 2.27)                                               0.91 (0.36, 2.29)
  50‐64                                                43                    129 812   0.33   70    141 811   0.49   1.49 (1.02, 2.18)[\*](#clc23223-note-0015){ref-type="fn"}       1.56 (1.06, 2.28)[\*](#clc23223-note-0015){ref-type="fn"}
  ≥65                                                  322                   633 295   0.51   284   464 663   0.61   1.19 (1.02, 1.40)[\*](#clc23223-note-0015){ref-type="fn"}       1.19 (1.01, 1.40)[\*](#clc23223-note-0015){ref-type="fn"}
  Comorbidity[a](#clc23223-note-0013){ref-type="fn"}                                                                                                                                 
  No                                                   22                    827 950   0.27   11    56 404    0.20   0.76 (0.37, 1.57)                                               1.02 (0.48, 2.19)
  Yes                                                  351                   716 751   0.49   354   606 501   0.58   1.19 (1.02, 1.38)[\*](#clc23223-note-0015){ref-type="fn"}       1.23 (1.06, 1.43)[\*\*](#clc23223-note-0016){ref-type="fn"}
  Hypertension                                         291                   502 799   0.58   254   356 329   0.71   1.23 (1.04, 1.45)[\*](#clc23223-note-0015){ref-type="fn"}       1.20 (1.01, 1.42)[\*](#clc23223-note-0015){ref-type="fn"}
  DM                                                   74                    222 088   0.33   70    152 216   0.46   1.38 (1.00, 1.92)                                               1.47 (1.06, 2.05)[\*](#clc23223-note-0015){ref-type="fn"}
  Hyperlipidemia                                       64                    110 929   0.58   52    78 388    0.66   1.15 (0.79, 1.65)                                               1.26 (0.87, 1.82)
  CHD                                                  187                   309 199   0.61   176   254 405   0.69   1.14 (0.93, 1.40)                                               1.19 (0.97, 1.47)
  Heart failure                                        102                   166 921   0.61   125   192 255   0.65   1.06 (0.82, 1.38)                                               1.15 (0.88, 1.50)
  COPD                                                 92                    136 483   0.67   79    101 140   0.78   1.15 (0.85, 1.56)                                               1.16 (0.86, 1.58)
  PAD                                                  14                    17 129    0.82   13    13 384    0.97   1.17 (0.55, 2.49)                                               1.22 (0.56, 2.62)
  CKD                                                  17                    30 967    0.55   14    22 952    0.61   1.13 (0.56, 2.30)                                               1.22 (0.60, 2.49)
  Hyperthyroidism                                      8                     19 883    0.40   2     18 760    0.11   0.28 (0.06, 1.29)                                               0.34(0.07, 1.64)
  Sleep disorders                                      14                    25 498    0.55   13    17 828    0.73   1.33 (0.62, 2.83)                                               1.40(0.65, 2.99)
  Gout                                                 56                    62 697    0.89   34    47 656    0.71   0.80 (0.52, 1.22)                                               0.82(0.54, 1.27)
  Cerebrovascular disease                              145                   264 166   0.55   119   183 467   0.65   1.18 (0.93, 1.51)                                               1.23 (0.97, 1.58)
  Chronic liver disease                                34                    75 110    0.45   32    44 747    0.72   1.58 (0.98, 2.57)                                               1.67 (1.03, 2.71)[\*](#clc23223-note-0015){ref-type="fn"}
  Cancer                                               22                    55 652    0.40   15    26 454    0.57   1.40 (0.73, 2.71)                                               1.40 (0.73, 2.71)
  Asthma                                               43                    79 031    0.54   30    57 735    0.52   0.94 (0.59, 1.51)                                               0.98 (0.61, 1.57)
  Peptic ulcer disease                                 104                   166 949   0.62   93    107 042   0.87   1.37 (1.04, 1.82)                                               1.37 (1.04, 1.82)[\*](#clc23223-note-0015){ref-type="fn"}
  VHD                                                  56                    98 491    0.57   78    106 329   0.73   1.29 (0.91, 1.81)                                               1.34 (0.95, 1.90)
  Follow‐up year                                                                                                                                                                     
  ≤1                                                   81                    180 323   0.45   128   159 000   0.81   1.77 (1.34, 2.34)[\*\*\*](#clc23223-note-0017){ref-type="fn"}   1.78 (1.34, 2.36)[\*\*\*](#clc23223-note-0017){ref-type="fn"}
  2‐3                                                  153                   283 691   0.54   108   225 350   0.48   0.89 (0.70, 1.14)                                               0.96 (0.75, 1.23)
  4‐5                                                  79                    172 659   0.46   65    137 604   0.47   1.03 (0.74, 1.43)                                               1.11 (0.79, 1.55)
  \>5                                                  60                    162 827   0.37   64    140 951   0.45   1.24 (0.87, 1.76)                                               1.36 (0.95, 1.95)

*Note*: Rate^\#^, incidence rate per 1000 person‐years.

Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HR, hazard ratio; PAD, peripheral artery disease; VHD, valvular heart disease.

Patients with any comorbidity of hypertension, diabetes mellitus, hyperlipidemia, CHD, heart failure, COPD, PAD, CKD, hyperthyroidism, sleep disorders, gout, cerebrovascular disease, chronic liver disease, cancer, asthma, peptic ulcer disease, and VHD were defined as the comorbidity group.

Model was adjusted for age, and comorbidities of hypertension, diabetes mellitus, and heart failure.

*P* \< .05

*P* \< .01

*P* \< .001.

4. DISCUSSION {#clc23223-sec-0014}
=============

Using Taiwan national cohort claims data, the authors addressed for the first time the bidirectional association between AD and AF. Considering that there is no previous large scale report on the association between AD and AF to date, this is indeed data that could be helpful in the understanding and management of the growing population of adults with AD and AF.

The topic of secondary AF has received increasing attention as prior anecdotal beliefs that AF resolved after resolution of acute illness triggers have yielded to evidence suggesting high AF recurrence, morbidity, and mortality after secondary AF.[14](#clc23223-bib-0014){ref-type="ref"} Patients with AD complicated AF might have an increased risk of AF‐associated adverse events resulting in premature mortality.[10](#clc23223-bib-0010){ref-type="ref"}, [11](#clc23223-bib-0011){ref-type="ref"}, [12](#clc23223-bib-0012){ref-type="ref"} The two pathologies, AD and AF, are essentially different diseases. It is possible that before the development of AF in AD, there may be several factors that are also considered to be a cause of AF incidence. However, we adopted a propensity score‐matching analysis and multivariate adjustment to minimize these biases and the results were statistically true,[13](#clc23223-bib-0013){ref-type="ref"} and we observed that such association was stronger in those without comorbidity, implying that the development of AF in patients with AD might be independent of comorbidities.

Identification of AD is of importance in patients with AF because of high risk of death from AD.[1](#clc23223-bib-0001){ref-type="ref"}, [2](#clc23223-bib-0002){ref-type="ref"} The current study showed that the risk ratio was highest among women, old age, and short follow‐up times; implying that more attention should be paid to these populations. The potential for higher incidence of AD in patients with AF, although has been corrected for covariates not adequately balanced in Table [3](#clc23223-tbl-0003){ref-type="table"}, it could be the case that AF and AD are two potential manifestation of possible variables not considered in the present study, without any pathophysiological relation.

AD, which might involve coronary injury, pericardial involvement, and other direct cardiac effects, could increase the risk of AF.[3](#clc23223-bib-0003){ref-type="ref"}, [4](#clc23223-bib-0004){ref-type="ref"}, [5](#clc23223-bib-0005){ref-type="ref"}, [6](#clc23223-bib-0006){ref-type="ref"}, [7](#clc23223-bib-0007){ref-type="ref"}, [8](#clc23223-bib-0008){ref-type="ref"}, [9](#clc23223-bib-0009){ref-type="ref"} However, there is no argument made in support of an association between AD and subsequent AF although several molecular mechanisms involving the atrial remodeling and weakness of the aortic walls might be possible explanations.[15](#clc23223-bib-0015){ref-type="ref"}, [16](#clc23223-bib-0016){ref-type="ref"}, [17](#clc23223-bib-0017){ref-type="ref"}, [18](#clc23223-bib-0018){ref-type="ref"} Such findings based on this big dataset deserved further investigation.

5. LIMITATIONS {#clc23223-sec-0015}
==============

First, the Taiwanese NHIRD has the power of large numbers, but it does not provide additional physiological insight. Second, diagnoses were retrieved from only inpatient files. This might introduce a bias, as AF patients with concomitant disorders might more often be hospitalized. Third, information about treatment was not collected in this study and this might have influenced the occurrence of both diseases and represents a possible bias in the interpretation of the results. Fourth, although we have used propensity matching and then conducted a multi‐variable analysis, it should be mentioned that uncontrolled potential confounders could be an issue in this type of study. Finally, the diagnostic accuracy of the diseases using ICD codes might be potentially the major limitation of the present study. However, this nationwide database has been validated and high accuracy was guaranteed.[19](#clc23223-bib-0019){ref-type="ref"}, [20](#clc23223-bib-0020){ref-type="ref"}, [21](#clc23223-bib-0021){ref-type="ref"}, [22](#clc23223-bib-0022){ref-type="ref"}

6. CONCLUSION {#clc23223-sec-0016}
=============

This is a study evaluating the relationship between the presence of AD and the incidence of AF and vice versa in a large numbers of patients from Taiwan. A positive association for both was found in this study.
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